Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki,...
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is undervalued on EV/EBITDA.
Target Price
The average target price of MAB.WA is 10.0 and suggests 21% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell